Omnicell (NASDAQ:OMCL) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Omnicell (NASDAQ:OMCL - Get Free Report) released its quarterly earnings data on Thursday. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12), Zacks reports. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Omnicell updated its Q1 2025 guidance to 0.150-0.250 EPS and its FY 2025 guidance to 1.650-1.850 EPS.

Omnicell Stock Up 5.6 %

OMCL stock traded up $2.24 during mid-day trading on Monday, reaching $42.40. The company had a trading volume of 787,845 shares, compared to its average volume of 391,782. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of 157.04, a PEG ratio of 26.98 and a beta of 0.78. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The stock has a 50 day simple moving average of $44.21 and a two-hundred day simple moving average of $43.48. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 0.95.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Benchmark reaffirmed a "buy" rating and issued a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Bank of America cut their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research report on Monday, January 6th. Craig Hallum increased their target price on Omnicell from $45.00 to $64.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. StockNews.com cut Omnicell from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Finally, JPMorgan Chase & Co. lifted their target price on Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research report on Thursday, November 21st. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $52.33.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares in the company, valued at approximately $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.64% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.